Full text is available at the source.
Abstract
Essence
Muscle preservation is framed as a central target for sustaining metabolic and cardiovascular benefits during incretin-based obesity pharmacotherapy.
Evidence
This review synthesizes emerging data that 25-40% of incretin-therapy weight loss may come from lean mass loss and discusses exercise, protein, creatine, and early adjunct drug strategies.
Caveat
Direct evidence on muscle function and strength remains limited, and proposed adjunct therapies are early rather than proven cardiovascular prevention tools.
Simplified
GLP-1 Therapies